Literature DB >> 25896519

Germline TP53 variants and susceptibility to osteosarcoma.

Lisa Mirabello1, Meredith Yeager2, Phuong L Mai2, Julie M Gastier-Foster2, Richard Gorlick2, Chand Khanna2, Ana Patiño-Garcia2, Luis Sierrasesúmaga2, Fernando Lecanda2, Irene L Andrulis2, Jay S Wunder2, Nalan Gokgoz2, Donald A Barkauskas2, Xijun Zhang2, Aurelie Vogt2, Kristine Jones2, Joseph F Boland2, Stephen J Chanock2, Sharon A Savage2.   

Abstract

The etiologic contribution of germline genetic variation to sporadic osteosarcoma is not well understood. Osteosarcoma is a sentinel cancer of Li-Fraumeni syndrome (LFS), in which approximately 70% of families meeting the classic criteria have germline TP53 mutations. We sequenced TP53 exons in 765 osteosarcoma cases. Data were analyzed with χ(2) tests, logistic regression, and Cox proportional hazards regression models. We observed a high frequency of young osteosarcoma cases (age <30 years) carrying a known LFS- or likely LFS-associated mutation (3.8%) or rare exonic variant (5.7%) with an overall frequency of 9.5%, compared with none in case patients age 30 years and older (P < .001). This high TP53 mutation prevalence in young osteosarcoma cases is statistically significantly greater than the previously reported prevalence of 3% (P = .0024). We identified a novel association between a TP53 rare variant and metastasis at diagnosis of osteosarcoma (rs1800372, odds ratio = 4.27, 95% confidence interval = 1.2 to 15.5, P = .026). Genetic susceptibility to young onset osteosarcoma is distinct from older adult onset osteosarcoma, with a high frequency of LFS-associated and rare exonic TP53 variants. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896519      PMCID: PMC4651039          DOI: 10.1093/jnci/djv101

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  36 in total

Review 1.  Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database.

Authors:  Simona Ognjanovic; Magali Olivier; Tracy L Bergemann; Pierre Hainaut
Journal:  Cancer       Date:  2011-08-11       Impact factor: 6.860

2.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.

Authors:  Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin
Journal:  Lancet Oncol       Date:  2011-05-19       Impact factor: 41.316

Review 3.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

4.  The codon 47 polymorphism in p53 is functionally significant.

Authors:  Xiaoxian Li; Patrick Dumont; Anthony Della Pietra; Cory Shetler; Maureen E Murphy
Journal:  J Biol Chem       Date:  2005-04-25       Impact factor: 5.157

5.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.

Authors:  Shih-Jen Hwang; Guillermina Lozano; Christopher I Amos; Louise C Strong
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

6.  Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study.

Authors:  Jessica Rb Musselman; Tracy L Bergemann; Julie A Ross; Charles Sklar; Kevin At Silverstein; Erica K Langer; Sharon A Savage; Rajaram Nagarajan; Mark Krailo; David Malkin; Logan G Spector
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15

7.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

8.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Using epidemiology and genomics to understand osteosarcoma etiology.

Authors:  Sharon A Savage; Lisa Mirabello
Journal:  Sarcoma       Date:  2011-03-08

10.  At-risk populations for osteosarcoma: the syndromes and beyond.

Authors:  George T Calvert; R Lor Randall; Kevin B Jones; Lisa Cannon-Albright; Stephen Lessnick; Joshua D Schiffman
Journal:  Sarcoma       Date:  2012-03-12
View more
  43 in total

Review 1.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

Review 2.  The pharmacogenomics of osteosarcoma.

Authors:  M Serra; C M Hattinger
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

3.  Nearly Half of TP53 Germline Variants Predicted To Be Pathogenic in Patients With Osteosarcoma Are De Novo: A Report From the Children's Oncology Group.

Authors:  Brandon J Diessner; Nathan Pankratz; Anthony J Hooten; Lisa Mirabello; Aaron L Sarver; Lauren J Mills; David Malkin; Ava C Kelley; Logan G Spector
Journal:  JCO Precis Oncol       Date:  2020-10-02

4.  FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.

Authors:  Hanjun Li; Xiuguo Han; Shengbing Yang; Yongjie Wang; Yang Dong; Tingting Tang
Journal:  Oncogene       Date:  2021-03-14       Impact factor: 9.867

Review 5.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

6.  Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk.

Authors:  Chenan Zhang; Joseph L Wiemels; Helen M Hansen; Julio Gonzalez-Maya; Alyson A Endicott; Adam J de Smith; Ivan V Smirnov; John S Witte; Libby M Morimoto; Catherine Metayer; Kyle M Walsh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

Review 7.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 8.  Clinical Outcomes of TP53 Mutations in Cancers.

Authors:  Ana I Robles; Jin Jen; Curtis C Harris
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

Review 9.  Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

Authors:  Pooja Hingorani; Katherine Janeway; Brian D Crompton; Cigall Kadoch; Crystal L Mackall; Javed Khan; Jack F Shern; Joshua Schiffman; Lisa Mirabello; Sharon A Savage; Marc Ladanyi; Paul Meltzer; Carol J Bult; Peter C Adamson; Philip J Lupo; Rajen Mody; Steven G DuBois; D Williams Parsons; Chand Khanna; Ching Lau; Douglas S Hawkins; R Lor Randall; Malcolm Smith; Poul H Sorensen; Sharon E Plon; Stephen X Skapek; Stephen Lessnick; Richard Gorlick; Damon R Reed
Journal:  Cancer Genet       Date:  2016-04-05

Review 10.  Li-Fraumeni Syndrome.

Authors:  Hernán Correa
Journal:  J Pediatr Genet       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.